استحکام داروهای ضد رماتیسم بیماری های بیولوژیک در بیماران مبتلا به آرتریت روماتوئید: تجزیه و تحلیل پایگاه اطلاعات بهداشتی ملی کره جنوبی

Adalimumab, etanercept, and infliximab had similar levels of persistence during the 1-year after treatment initiation, when used as first-line treatment. However, when used as a subsequent-line treatment, etanercept and abatacept had higher persistence than infliximab or adalimumab. Persistence could be a consideration when selecting the subsequent-line biologic treatment for patients with rheumatoid arthritis in South Korea.